GlassScriptPhysician profile
Steve W Rucker
NPI 1083712806
$67,042.74
in general payments reported to CMS, 2019-2025
73 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $8,491 · 2021: $10K · 2022: $7,149 · 2023: $3,177 · 2024: $2,428 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $6,802 · Travel and Lodging: $2,210 · Education: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,820.00 |
| Food and Beverage | $6,802.34 |
| Travel and Lodging | $2,209.53 |
| Education | $517.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,066.78 | 2019-2025 | Jardiance, Synjardy |
| Vifor Pharma, INC. | $18,019.54 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $11,822.06 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Opko Pharmaceuticals, LLC | $2,366.72 | 2019-2025 | Rayaldee |
| Lilly USA, LLC | $2,121.52 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,389.04 | 2019-2025 | Repatha, Evenity, Repatha |
| Otsuka America Pharmaceutical, INC. | $1,348.43 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $1,208.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $876.81 | 2019-2025 | Aveir, Freestyle Libre 3, Mitraclip |
| Abbvie INC. | $859.47 | 2019-2025 | Ubrelvy, Vraylar |
| Novartis Pharmaceuticals Corporation | $833.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $773.42 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $703.58 | 2019-2020 | |
| Horizon Therapeutics Plc | $552.86 | 2019-2023 | Krystexxa |
| Pfizer INC. | $479.75 | 2019-2025 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Rucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.